This Chinese medicine stock closed up and won the second board!

【Pharmaceutical Network Pharmaceutical Stock Market】Among the popular stocks on November 15, traditional Chinese medicine stocks performed well with Ling Pharmaceutical
.
The stock closed at 37.
76 yuan, with a turnover of 4.
268 billion, a turnover rate of 8.
39%, and a price-to-earnings (TTM) of 41.
11
.
Since October, Yiling Pharmaceutical has risen by more than 70%.

The analysis believes that the reasons for the stock's limit include traditional Chinese medicine + innovative drugs + Lianhua Qingwen + pharmaceutical e-commerce
.
The company is mainly committed to the research and development, production and sales
of patented innovative traditional Chinese medicine.
The company has GMP certified capsules, tablets, granules, injection production lines, and EU certified chemical preparation workshops
.
Its Lianhua Qingwen products have considerable sales, and the data shows that in 2021, the company's Lianhua Qingwen products achieved an operating income of 4.
06 billion yuan, accounting for 40.
15%
of the company's total operating income.
According to the 2022 half-year report, Yiling Pharmaceutical's market share of Lianhua Qingwen products has increased year by year
.
Recently, on the interactive platform, in response to investors' questions about whether Lianhua Qingwen and Lianhua cough products are fully prepared for government storage and storage, the company said that it will closely track market demand, adjust production and sales plans in a timely manner, and make every effort to ensure market supply
.
Yiling Pharmaceutical focuses on innovative R&D, and in 2021, the company invested nearly 800 million yuan in R&D, accounting for nearly 8%
of R&D investment.
From Q1 to Q3 this year, the R&D expenditure of Yiling Pharmaceutical was 552 million yuan, and the R&D expense rate was 6.
94%, an increase of 0.
32pct
year-on-year.
With continuous R&D investment, the company's products under development are progressing smoothly, including in the field of research and development of innovative drugs in traditional Chinese medicine, the 2022 semi-annual report shows that the company has entered the clinical stage of 4 Class 1 innovative drugs, and a number of Class 1 innovative drugs are in the preclinical research stage, of which anilineprofen injection has completed clinical phase III, pre-NDA communication, and will soon declare NDA
.
On the evening of November 15, the company announced that it received the "Notice of Acceptance" approved and issued by the State Medical Products Administration on November 14, and the clinical trial of the domestic production of Huoxia cold granules was accepted
.
The proposed functions of Huoxia cold granules are: to solve the table and neutralize, to remove pollution and moisture
.
It is used for cold wind attack table, wet blockage, symptoms include fever, bad wind, nasal congestion and runny nose, headache, nausea and vomiting, diarrhea, heavy limbs, abdominal distention and pain, less food and sluggishness
.
With the increase in the penetration rate of pharmaceutical e-commerce, the outflow trend of prescription drugs, and the access of medical insurance payment to pharmaceutical e-commerce, the transaction scale is expected to increase from 195.
6 billion yuan in 2020 to 243.
1 billion yuan in 2022.

It is reported that Yiling Pharmaceutical has established an e-commerce marketing system, which complements traditional ground marketing, and combines online health mall with ground terminal marketing, combining "medicine, medicine, health and health care", so as to form a new field
for the company's rapid development in the future.
According to the third quarter report of 2022, the company achieved operating income of 2.
38 billion yuan, a year-on-year increase of 7.
41%; The net profit was 366 million yuan, a year-on-year increase of 40.
92%.

In the first three quarters, the operating income was 7.
946 billion yuan, a year-on-year decrease of 2.
04%; The net profit attributable to the parent was 1.
414 billion yuan, a year-on-year increase of 15.
58%.

In addition to Yiling Pharmaceutical, individual stocks such as Teyi Pharmaceutical, Guizhou Sanli, and Huangshan Capsules also performed prominently
.
The analysis believes that this is related to the implementation of the "20 articles" of optimization of prevention and control, and many institutions said that medicine has a comparative advantage, optimistic about the structural market "20", and the policy optimization will be conducive to the recovery of conventional medical demand and the recovery
of consumer medical demand.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.